US-funded research into the health of people abroad has large health and economic benefits for Americans.
Articles on Health policy
Displaying 1 - 20 of 548 articles
People at the highest risk of severe COVID will still be eligible for free vaccines. Others may have to pay.
Leave for the non-birthing parent after a new baby arrives gives the family an opportunity to bond.
South Korea’s unusually rapid transition to a super-aged society means it has had little time to find solutions for pension funding and healthcare for the elderly.
Portugal’s remarkable public health strides after changing its approach to drugs may not be replicable in other countries absent broader systemic reforms.
Government critics say changes to health insurance rebates will strain the public health system. But the evidence shows the impact might not be what you think.
Monoclonal antibody drugs like Keytruda attack cancer cells in a different way to chemotherapy drugs.
Measles is making a comeback around the world. In places with low vaccination rates, a few cases can quickly become an epidemic.
A recent case involving a patient harmed in an overcrowded ED highlights the need for a fresh look at how NZ investigates clinical errors.
Large datasets can be useful research tools, but current government efforts to gather medical records depend on policy and technology that falls short of protecting people’s privacy.
The government wants to cut $37.8 billion from the NDIS over 4 years. Much of this will come from tightening access to the scheme and reducing participants’ plans.
Trump’s latest executive order is set to lead to delayed vaccinations, falling coverage and a resurgence of diseases once brought under control.
New research shows what happens if the extra health insurance rebate for over-65s is scrapped, as planned. Here’s why the sky won’t fall in.
Social care reform has failed in the UK for 25 years. Four international examples show what a lasting fix actually requires.
It’s hard to know exactly how big an issue this is today, whether this is becoming more common or how much it costs taxpayers. But here’s what we know so far.
This is just one example of an online trend with real-world health consequences.
International drug companies are threatening to remove medicines from the market if Australia doesn’t offer them a better price. Here’s what’s at stake.
Biological samples and data from Aboriginal and Torres Strait Islander peoples have been misused in the past. So how would we make a new screening program safer?
A new FDA fast-track program could undermine the agency’s role as a global drug safety authority.
From October 1, specially qualified nurses will be able to prescribe medications and renew scripts at the subsidised price.
Top contributors
-
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
-
Program Director, Health and Aged Care, Grattan Institute
-
Professor of Health Economics, The University of Melbourne
-
Professor of Health Economics and Director, Centre for Health Economics, Monash Business School, Monash University
-
Professor, Public Service Research, UNSW
-
Jim Gillespie is a Friend of The Conversation.
Associate Professor in Health Policy, Leeder Centre for Health Policy, Economics and Data & Sydney School of Public Health, University of Sydney
-
Reader in Health Economics, Centre for Health Economics, University of York
-
Professor and Director, Macquarie University Centre for the Health Economy, Macquarie University
-
Adjunct Associate Professor, Menzies Centre for Health Policy and Economics, University of Sydney
-
Lecturer, Public Sector Finance, University of Canberra
-
Professor of Health Economics, University of Technology Sydney
-
Associate Professor, Brain and Mind Centre, University of Sydney; University of Canberra
-
Emeritus Professor, Menzies Centre for Health Policy, University of Sydney
-
Emeritus Professor of Public Health, La Trobe University
-
Professor of Health Economics and Director, Centre for Health Economics Research and Evaluation, University of Technology Sydney